NCT02105766View on ClinicalTrials.gov

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 21, 2014

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2027

Conditions
Sickle Cell DiseaseThalassemiaStem Cell TransplantationGraft vs Host Disease
Interventions
DRUG

Alemtuzumab

Immunosuppressant

DRUG

Sirolimus

Immunosuppressant

DRUG

Cyclophosphamide

Immunosuppressant

DRUG

Pentostatin

Immunosuppressant

PROCEDURE

Radiotherapy

Immunosuppressant and myelosuppressant

DRUG

Filgrastim

mobilize peripheral blood stem cells for apheresis collection

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health Clinical Center (CC)

NIH

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02105766 - Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure | Biotech Hunter | Biotech Hunter